DRIO — DarioHealth Income Statement
0.000.00%
- $31.18m
- $31.46m
- $27.04m
- 40
- 63
- 38
- 44
Annual income statement for DarioHealth, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.58 | 20.5 | 27.7 | 20.4 | 27 |
Cost of Revenue | |||||
Gross Profit | 2.51 | 3.96 | 9.65 | 5.98 | 13.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 37.5 | 97 | 88.9 | 81.4 | 89.1 |
Operating Profit | -29.9 | -76.5 | -61.3 | -61.1 | -62 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29.4 | -76.7 | -62.2 | -59.4 | -44.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -29.4 | -76.8 | -62.2 | -59.4 | -42.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -29.4 | -76.8 | -62.2 | -59.4 | -42.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.1 | -78.8 | -63.8 | -63.5 | -41 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.55 | -4.71 | -2.58 | -2.12 | -0.756 |